Our Focus
Kinled has a long track record in financing deep technological breakthroughs in advanced medical devices, robotics, precision medicine, drug discovery, and neuromodulation.
The Aisher family has founded and invested in innovative businesses for over a century. Learn more about our early days and track record by reading our family history:
Today we hold a portfolio of 175 investments in innovative companies, both directly and through specialised funds.
In life sciences, we have a laser-focus on innovation in the biomedical technology, medical devices, robotics, neuromodulation, and digital healthcare services sectors, which represents over 50% of our portfolio.
In digital technologies, we invest in SaaS-enabled networks and marketplaces, with a strong emphasis on digital heath, where technology can democratize markets and provide consumers with greater choice of services, representing 25% of our portfolio.
In fintech, we invest in companies that use technology to challenge the traditional established institutions by providing superior service in embedded payment platforms, insurance, real estate, lending and banking, which represents 25% of our portfolio.
Kinled is also a Founding Partner/Director/Limited Partner in ten independent funds. This includes four dedicated Life Science investment companies managed from Vienna and Zurich, with combined Assets under Management of €300M; and six Digital Technology Funds based in Vienna, Zurich, London/Copenhagen, Prague/Bratislava, and Helsinki with combined Assets under Management of €225M.
Fostering Innovation
Our corporate team is dedicated to identifying and nurturing groundbreaking opportunities within the Life Sciences, Digital, and FinTech sectors
We have proudly funded early stage businesses in Austria and Switzerland that originated in Universities such as Zürich, Bern, Fribourg, Geneva, Lausanne, Graz, Innsbruck, and Vienna and have a substantial track record of developing successful international businesses from within with the Innovation Park at the Swiss Federal Institute of Technology and the BioCampus of the University of Vienna, where we maintain offices and laboratories.
In the United States, we funded early stage businesses that originated in Universities from Boston, Cambridge, Harvard, Houston, Massachusetts Institute of Technology, Michigan, New York, Northeastern, San Diego, San Francisco, to Stanford.
In Europe Kinled portfolio firms were created with technology from Universities such as Aix-Marseille, Amsterdam, Barcelona, Debrecen, Gdansk, Helsinki, Ljubljana, Linköping, Milan, London, Paris, Pecs, Prague, Utrecht, and Warsaw.
To learn more about some of successful exits, Click Here >
Opportunities
Kinled harbours a commitment to transforming academic ventures into thriving commercial entities.
This vision has been actualised through the establishment of three venture accelerators in Austria and Switzerland, along with a suite of regulated funds designed to underpin these ventures. Moreover, our strategic co-investments with leading venture capital firms and family offices stand as a testament to our collaborative approach and our commitment to innovation.
Kinled has created a number of mechanisms to allow co-investment from sophisticated and qualified family-offices who wish to support us in developing academic/scientific projects and nascent technologies.
Today all our investments are processed through independently-managed incubator/accelerators that Kinled is a founder shareholder in, and two EU regulated funds that we manage, as well as a special opportunity investment company that co-invests with a number of Swiss, EU, US, and UK regulated and un-regulated technology funds, that we are partners in.
Cebina The Central European Biotech Incubator & Accelerator at the University of Vienna’s Campus Biotech, supports innovative biotechnology companies focused on inflammation, neurology and ageing.
Mountain Labs is a start-up incubator and technology investment facilitator, sourcing new deep technology investment opportunities in artificial intelligence, quantum computing, and brain computer interface.
Danube BioVentures - Danube BioVentures operates a series of venture capital funds geared towards pharmaceutical drug development and biomedical innovations emerging from early-stage projects, with a strong focus on dementia. Working with over a dozen European Universities, and the United Nations Centre for Genetic Engineering and Biotechnology, Danube BioVentures provides investors with access to the evolving biotech and pharmaceutical sector, benefiting from the deep scientific and market knowledge of our strategic partners.
Our Due Diligence Process
A significant part of our strategy is based upon our superior deal flow and extremely rigorous due diligence.
Our executives are principally managed from offices from Hong Kong, Zurich and Vienna. We also have offices in Gibraltar, London & Shanghai. Kinled are Partners in ten independently managed regulated and unregulated highly focussed funds, some of which we founded. Four are dedicated Life Science investment companies managed from Vienna and Zurich, with combined Assets under Management of €300M; and six are Digital Technology Funds based in Vienna, Zurich, London, Prague, Bratilslava, and Helsinki, with Assets under Management of €225M.
We also have very strong relations with number of portfolio companies in New York, Sao Paolo, Buenos Aires, and Miami, which are managed by Kinled executives. In the US, Kinled has 16 portfolio businesses, and we work closely with a number of specialised investors across the country, frequently co-investing in space and defence technology with renowned University alumni, and in cardiology with selected experts based in California.
We like to stay close to our founders, entrepreneurs, and are an active investor, meaning that our team, or fund partners, take an active role in the management and direction of our portfolio companies, using our shareholding position to positively influence business strategy.
There are areas that we have really specific expertise in, where we believe our industry expertise is unparalleled. We are dedicated to drug discovery and pioneering research into tangible solutions for severe illness, as well as to emerging fields of regenerative medicine, robotics, bionics, financial and digital technologies.
Annually we see over 2000 business plans, leading to 150 pre-screened opportunities to complete deep due diligence on - knowing that they have been approved by the most rigorous legal and commercial team in the industry, and generally invest in 2 to 4 companies.
Family Office
We are often asked whether Kinled is a “Family Office.” Our Chairman, Patrick Aisher, doesn’t hesitate:
“Absolutely not. ‘Family Office’ is a dreadful term—dreamt up by banks, accountants, and consultants to describe a rigid, generic structure that exists purely to preserve wealth, inflate egos, and rack up fees for advisors.” At Kinled, we believe in creating wealth—not just financial, but in opportunity, purpose, and progress—for our partners, team members, co-investors, and portfolio and fund shareholders. We’re proud to do so alongside carefully selected funds and investment vehicles, some of which we manage directly, and some managed by other trusted partners.
Sir Owen Aisher – (1900-1993)
Jack Aisher – (1910-2008)
Owen Aisher – (1876-1963)
Patrick Aisher
Funds
10% of our investments are through specialised funds.
Over the years, Kinled has seeded, created, invested, and partnered with a number of regulated and unregulated funds. Today we are proud to be a Founding/Limited Partner in the following 10 funds >
Please click here to learn more about our portfolio of 175 investments, access our private client site, or see our locations >
Our Portfolio
